T cell replacement therapy - Fred Hutchinson Cancer Research Center
Alternative Names: Activated-T-cell-therapy; T cell therapy; T lymphocyte therapyLatest Information Update: 16 Jan 2022
At a glance
- Originator Fred Hutchinson Cancer Research Center
- Developer Fred Hutchinson Cancer Research Center; Targeted Genetics Corporation
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cytomegalovirus infections; HIV infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-infections in USA (IV, Infusion)
- 19 Oct 1995 Phase-I clinical trials for Cytomegalovirus infections in USA (IV)